Novavax Secures $125 Million Milestone Payment from Sanofi
PUBLIC · NVAXOct 29, 2026
Amount Raised
$125 Million
Round Type
Funding Round
Gaithersburg
Investors
Sanofi Pasteur Inc.
Description
On October 28, 2026, Novavax announced that its partner Sanofi Pasteur Inc. dosed the fifth patient in a Phase 3 trial for a combination influenza-COVID-19 vaccine. This milestone has triggered a $125 million payment under Novavax's Collaboration and License Agreement with Sanofi. The company expects to receive this payment by the first quarter of 2027
Who to call at Novavax, and when
A new round usually means Novavax is about to hire and buy. The teams that reach out first get the meeting.
An alert the day Novavax raises, hires an executive or expands, scored against what you sell
The decision-makers there, with verified emails
Who you already know at Novavax, from your own LinkedIn network
Works inside ChatGPT and Claude. Ask who to call at Novavax. With Fundz connected, it knows.
Trusted byOracleSnowflakeCloudflareLinkedInGoogleSalesforce★★★★★4.8/5 on G2
Company Information
Company
Novavax
Location
Gaithersburg, Maryland, United States
About
We’re making a difference in the health of people around the world by producing next generation vaccines that are accessible to more people. We stand strong against infectious diseases and viral threats—our science grounds us, our technology pushes us forward, our commitment inspires us to achieve our hopes. We do this work for the greater health of people everywhere. It’s more than our job. It’s our passion.
AI made execution free. Knowing first is the whole game now.
Fundz sees it the moment Novavax raises, hires an exec or expands, usually minutes after it happens, and tells you who to reach.
Gaithersburg